Clinical Trial Update: A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update covers a dose-escalation/expansion study of OP-1250 in advanced HR+, HER2- breast cancer, which completed Phase 1 and Phase 2. No specific results a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• OP-1250 (OP-1250)

Snippet

Sponsor: Olema Pharmaceuticals, Inc. | Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED